Tomo is a digital mortgage platform for the real estate industry.

Register To Buy and Sell Shares

For more details on financing and valuation for Tomo, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Tomo’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tomo.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Tomo’s Stock

plusminus
Can you buy Tomo’s stock?
Tomo is not publicly traded on NYSE or NASDAQ in the U.S. To buy Tomo’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Tomo’s stock?
Yes, you can sell stock of a private company like Tomo. Forge can help you sell your Tomo stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Tomo’s stock price?
Tomo is a privately held company and therefore does not have a public stock price. However, you may access Tomo’s private market stock price with Forge Data.
plusminus
What is Tomo’s stock ticker symbol?
Tomo does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Accuray unveils Radixact System update, highlights Tomo C approval
"Accuray, in partnership with Limbus AI, has introduced an update for its Radixact System, which is pending 510(k) clearance from the U.S. Food and Drug Administration. The company has also received approval from China’s National Medical Products Administration for its Tomo C radiation treatment delivery system. The updates will allow medical teams to quickly adjust treatment plans if needed while the patient is still on the treatment table, improving efficiency and adaptability in treatment sessions. "
Updated on: Feb 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.